Since severe LV failure often causes increased lung weight and WHO class II pulmonary hypertension, and since HF-induced lung remodeling also affects the clinical outcome in HF patients, we further determined the effect of anti-IL12β antibody on TAC-induced pulmonary function using SCIREQ’s flexiVent system. The gene discussed is IL12B; the disease is pulmonary arterial hypertension.